Drugs / M1-c6v1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06046742 | Jul 2024 → Jun 2028 expected | neoplasm | Guangzhou Virotech Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT04665362 | Jan 2021 → Jun 2022 | hepatocellular carcinoma | Liang Peng | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M1-c6v1 | “Drug: Recombinant oncolytic virus M1 Recombinant oncolytic virus M1 is administered intravenously 1×109 CCIC50 once daily on day1-5, every 28 day cyle. Other name：M1-c6v1” NCT04665362 ↗ |
| Route | Intravenous | “administered intravenously” NCT04665362 ↗ |